Skip to main content

Table 3 The Vitiligo European Task Force scores at baseline and week 12, n = 11

From: Ginkgo biloba for the treatment of vitilgo vulgaris: an open label pilot clinical trial

area

 

% area (SD)

staging (0-3) (SD)

spreading (-1 to 1) (SD)

head and neck (0-9%)

baseline

0.79 (0.94)

1.55 (0.93)

0.73 (0.47)

 

week 12

0.73 (0.83)

1.27 (0.90)

-0.36 (0.50)

 

change

-0.06 p = 0.27

-0.27 p = 0.21

-1.09 p = 0.00

trunk (0-36%)

baseline

1.33 (1.31)

1.55 (1.04)

0.82 (0.40)

 

week 12

1.30 (1.30)

1.45 (1.04)

-0.45 (0.52)

 

change

-0.03 p = 0.21

-0.09 p = 0.36

-1.27 p = 0.00

arms (0-18%)

baseline

1.81 (2.17)

1.36 (0.81)

0.55 (0.52)

 

week 12

1.77 (2.06)

1.27 (0.79)

-0.09 (0.54)

 

change

-0.05 p = 0.36

-0.09 p = 0.36

-0.64 p = 0.00

legs (0-36%)

baseline

1.99 (2.25)

2.09 (0.54)

0.64 (0.50)

 

week 12

1.76 (1.76)

1.82 (0.75)

-0.27 (0.79)

 

change

-0.23 p = 0.26

-0.27 p = 0.09

-0.91 p = 0.02

totals (0-100%)

baseline

5.91 (4.53)

6.55 (1.92)

2.73 (1.35)

 

week 12

5.56 (4.27)

5.82 (1.94)

-1.18 (1.25)

 

change

-0.36 p = 0.10

-0.73 p = 0.10

-3.91 p = 0.00

  1. SD, standard deviation